AWM
AVBP icon

Avior Wealth Management’s ArriVent BioPharma AVBP Stock Holding History

Avior Wealth Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-996
Closed -$26.5K – 2396
2024
Q4 		$26.5K Buy
996
+108
+12% +$3.1K ﹤0.01% 1349
2024
Q3 		$20.9K Buy
888
+498
+128% +$11.3K ﹤0.01% 1367
2024
Q2 		$7.23K Buy
+390
New +$6.96K ﹤0.01% 1606

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avior Wealth Management's AVBP Position: Q1 2025 in Review

Avior Wealth Management sold out of ArriVent BioPharma (AVBP) in Q1 2025, closing a stake of 996 shares — an estimated $26.5K sold.

Avior Wealth Management first reported a position in AVBP in Q2 2024 and held it in 3 quarters. The position peaked at $26.5K in Q4 2024. 83 funds tracked by Wall St. Rank hold AVBP as of Q1 2025.

  • Avior Wealth Management reported no remaining ArriVent BioPharma position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 996 ArriVent BioPharma shares in Q1 2025, an estimated $26.5K.
  • Avior Wealth Management first reported a position in ArriVent BioPharma in Q2 2024 and held it in 3 quarters.
  • Avior Wealth Management's ArriVent BioPharma position peaked at $26.5K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.